NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, Antonio C. Wolff

Research output: Contribution to journalReview article

Abstract

The NCCN Task Force on Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry was convened to critically evaluate the extent to which the presence of the estrogen receptor (ER) and progesterone receptor (PgR) biomarkers in breast cancer serve as prognostic and predictive factors in the adjuvant and metastatic settings, and the ability of immunohistochemical (IHC) detection of ER and PgR to provide an accurate assessment of the expression of these biomarkers in breast cancer tumor tissue. The task force is a multidisciplinary panel of 13 experts in breast cancer who are affiliated with NCCN member institutions and represent the disciplines of pathology, medical oncology, radiation oncology, surgical oncology, and biostatistics. The main overall conclusions of the task force are ER is a strong predictor of response to endocrine therapy; ER status of all samples of invasive breast cancer or ductal carcinoma in situ (DCIS) should be evaluated by IHC; IHC measurements of PgR, although not as important clinically as ER, can provide useful information and should also be performed on all samples of invasive breast cancer or DCIS; IHC is the main testing strategy for evaluating ER and PgR in breast cancer and priority should be given to improve the quality of IHC testing methodologies; all laboratories performing IHC assays of ER and PgR should undertake formal validation studies to show both technical and clinical validation of the assay in use; and all laboratories performing IHC assays of hormone receptors in breast cancer should follow additional quality control and assurance measures as outlined in the upcoming guidelines from the American Society of Clinical Oncology and College of American Pathologists.

Original languageEnglish (US)
Pages (from-to)S1-S21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue numberSUPPL. 6
StatePublished - Oct 23 2009
Externally publishedYes

Keywords

  • Breast cancer
  • Clinical validation
  • Endocrine therapy
  • Estrogen receptor
  • False-negative rate
  • Immunohistochemistry
  • NCCN Clinical Practice Guidelines in Oncology
  • Progesterone receptor
  • Quality assurance
  • Quality control
  • Technical validation

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry'. Together they form a unique fingerprint.

  • Cite this

    Allred, D. C., Carlson, R. W., Berry, D. A., Burstein, H. J., Edge, S. B., Goldstein, L. J., Gown, A., Hammond, M. E., Iglehart, J. D., Moench, S., Pierce, L. J., Ravdin, P., Schnitt, S. J., & Wolff, A. C. (2009). NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. JNCCN Journal of the National Comprehensive Cancer Network, 7(SUPPL. 6), S1-S21.